Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials

OBJECTIVE: To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA). METHODS: Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Helliwell, Philip S, Hjuler, Kasper Fjellhaugen, Raymond, Kyle, McInnes, Iain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815636/
https://www.ncbi.nlm.nih.gov/pubmed/33106286
http://dx.doi.org/10.1136/annrheumdis-2019-216835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815636/
https://www.ncbi.nlm.nih.gov/pubmed/33106286
http://dx.doi.org/10.1136/annrheumdis-2019-216835

Ejemplares similares